Neuroprotective Potential of Dimethyl Fumarate-loaded Polymeric Nanoparticles against Multiple Sclerosis

被引:10
|
作者
Ojha, Smriti [1 ]
Kumar, Babita [2 ]
Chadha, Hina [1 ]
机构
[1] Vishveshwarya Grp Inst, Dept Pharm, Gb Nagar 203207, Noida, India
[2] Sanskar Educ Grp, Dept Pharm, Ghaziabad 201302, India
关键词
Multiple sclerosis; chitosan nanoparticles; cuprizone model; SH-SY5Y cells; bioavailability; SOLID LIPID NANOPARTICLES; IN-VITRO; MANAGEMENT; BG-12; BRAIN; RAT;
D O I
10.36468/pharmaceutical-sciences.535
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the present study was to access the potential of dimethyl fumarate-loaded chitosan polymeric nanoparticles for the management of multiple sclerosis. Dimethyl fumarate-loaded chitosan nanoparticles were prepared by polyelectrolyte complex coaservation technique. The prepared nanoparticles were characterized and found to have an average particle size of 324 nm, zeta potential of -34.85 mV and a poly dispersity index of 0.367. The entrapment efficiency was found to be 65.36 % and the drug loading was 28 %. The formulation's in vitro drug release profile and stability parameters were also evaluated. Cumulative percent drug release was found to be 84 % up to 24 hours and the formulation was found to be stable at 28 degrees for 90 days. In vitro neuroprotective effect of the nanoformulation was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay on human neuroblast SH-SY5Y cells and the treated cells showed improved cell viability under hydrogen peroxide-induced cell apoptosis. In vivo cuprizone model for multiple sclerosis in rodents also confirmed these findings by showing a significant increase in locomotion score.
引用
收藏
页码:496 / 502
页数:7
相关论文
共 50 条
  • [41] Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature
    Russo, Cinzia Dello
    Scott, Kathryn Anne
    Pirmohamed, Munir
    PHARMACOLOGY & THERAPEUTICS, 2021, 219
  • [42] Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome
    Okuda, Darin T.
    Kantarci, Orhun
    Lebrun-Frenay, Christine
    Sormani, Maria Pia
    Azevedo, Christina J.
    Bovis, Francesca
    Hua, Le H.
    Amezcua, Lilyana
    Mowry, Ellen M.
    Hotermans, Christophe
    Mendoza, Jason
    Walsh, John S.
    von Hehn, Christian
    Vargas, Wendy S.
    Donlon, Stacy
    Naismith, Robert T.
    Okai, Annette
    Pardo, Gabriel
    Repovic, Pavle
    Stuve, Olaf
    Siva, Aksel
    Pelletier, Daniel
    ANNALS OF NEUROLOGY, 2023, 93 (03) : 604 - 614
  • [43] Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
    Laplaud, David-Axel
    Casey, Romain
    Barbin, Laetitia
    Debouverie, Marc
    De Seze, Jerome
    Brassat, David
    Wiertlewski, Sandrine
    Brochet, Bruno
    Pelletier, Jean
    Vermersch, Patrick
    Edan, Gilles
    Lebrun-Frenay, Christine
    Clavelou, Pierre
    Thouvenot, Eric
    Camdessanche, Jean-Philippe
    Tourbah, Ayman
    Stankoff, Bruno
    Al Khedr, Abdullatif
    Cabre, Philippe
    Lubetzki, Catherine
    Papeix, Caroline
    Berger, Eric
    Heinzlef, Olivier
    Debroucker, Thomas
    Moreau, Thibault
    Gout, Olivier
    Bourre, Bertrand
    Wahab, Abir
    Labauge, Pierre
    Magy, Laurent
    Defer, Gilles
    Guennoc, Anne-Marie
    Maubeuge, Nicolas
    Labeyrie, Celine
    Patry, Ivania
    Nifle, Chantal
    Casez, Olivier
    Michel, Laure
    Rollot, Fabien
    Leray, Emmanuelle
    Vukusic, Sandra
    Foucher, Yohann
    Fontaine, B.
    Marignier, R.
    Durand-Dubief, F.
    Mathey, G.
    Le Page, E.
    Peaureaux-Averseng, D.
    Ouallet, J. C.
    Ruet, A.
    NEUROLOGY, 2019, 93 (07) : E635 - E646
  • [44] NONFATAL PML IN A PATIENT WITH MULTIPLE SCLEROSIS TREATED WITH DIMETHYL FUMARATE
    Baharnoori, Moogeh
    Lyons, Jennifer
    Dastagir, Akram
    Koralnik, Igor
    Stankiewicz, James M.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2016, 3 (05):
  • [45] Dimethyl Fumarate (Tecfidera): A New Oral Agent for Multiple Sclerosis
    Venci, Jineane V.
    Gandhi, Mona A.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (12) : 1697 - 1702
  • [46] Discontinuation of dimethyl fumarate in relapsing multiple sclerosis in a single centre
    Dorsey-Campbell, R.
    Motlagh, B. Esfahani
    Quinn, T.
    Delacruz, D.
    Felongco, T.
    Walters, P.
    Scalfari, A.
    Singh-Curry, V.
    Malik, O.
    Nicholas, R.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 893 - 894
  • [47] Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis
    Diebold, Martin
    Sievers, Claudia
    Bantug, Glenn
    Sanderson, Nicholas
    Kappos, Ludwig
    Kuhle, Jens
    Lindberg, Raija L. P.
    Derfuss, Tobias
    JOURNAL OF AUTOIMMUNITY, 2018, 86 : 39 - 50
  • [48] Liver injury associated with dimethyl fumarate in multiple sclerosis patients
    Munoz, Monica A.
    Kulick, Corrinne G.
    Kortepeter, Cindy M.
    Levin, Robert L.
    Avigan, Mark I.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (14) : 1947 - 1949
  • [49] Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate
    Wood, Callum H.
    Robertson, Neil P.
    Htet, Zin Min
    Tallantyre, Emma C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 58
  • [50] An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis
    Valencia-Sanchez, Cristina
    Carter, Jonathan L.
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (12) : 1399 - 1405